COMPARTIVE ANIMAL CORE

比较动物核心

• 批准号: 8516645
• 负责人: Cheryl A London
• 金额: $ 23.33万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-05 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516645
• 关键词: Adverse effects; Adverse event; Aftercare; Anatomy; Animal Model; Animals; Antineoplastic Agents; Biological Markers; Canis familiaris; Childhood; Clinical; Clinical Trials; Comparative Pathology; Development; Diagnosis; Disease; Drug Kinetics; Evaluation; Future; Genetic Engineering; Goals; Housing; Human; In Vitro; Individual; Instruction; London; Malignant Neoplasms; Maximum Tolerated Dose; Medical Oncologist; Modeling; Mus; Normal tissue morphology; Oncology; PTPRC gene; Pathologist; Pathology; Patients; Pharmacodynamics; Phenotype; Process; Program Research Project Grants; Progression-Free Survivals; Research Personnel; Resource Sharing; Sampling; Specimen; Standardization; Testing; Therapeutic; Tissue Banking; Tissue Banks; Tissue Sample; Toxic effect; Tumor Tissue; Veterinary Medicine; Veterinary Pathology; Work; Xenograft procedure; anti-cancer therapeutic; college; comparative; design; drug candidate; drug development; drug discovery; experience; inhibitor/antagonist; mouse model; novel; novel therapeutic intervention; novel therapeutics; osteosarcoma; patient population; research and development; response; sarcoma; small molecule; success; therapeutic target; tool; tumor

The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics; 2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas; and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.

比较动物核心的总体目标是支持本计划项目资助中使用的动物模型的开发和使用。比较动物核心的指导原则是组织和肿瘤样本的有效规划和利用、处理和诊断的标准化以及犬自发性肿瘤动物模型的持续开发。这个核心是安置和协调在兽医生物科学在俄勒冈州立大学兽医学院的部门，包括在比较病理学，组织库，临床试验开发和执行的专业知识的个人。Cheryl伦敦博士是一名委员会认证的兽医肿瘤学家，在癌症药物开发方面拥有广泛的专业知识，包括验证新靶标、识别用于靶点抑制的适当小分子以及在相关犬癌症中测试这些化合物，目的是提供有助于人类药物开发过程的关键信息。共同研究者Krista La Perie和布拉德Bolon博士是兽医解剖病理学委员会认证，是比较病理学领域的专家，特别是在小鼠癌症模型和这些模型中新型疗法的评价方面。本核心的主要目标是协助研究人员确定小鼠肉瘤模型中与新型治疗方法相关的毒性和活性，确定可能在临床环境中取得成功的候选药物/治疗方法，并评估这些治疗方法。自发性肉瘤犬作为未来人体临床试验的前奏。因此，本核心的具体目的是：1）提供各种靶向治疗剂治疗后小鼠疾病模型中产生的肉瘤的标准化组织病理学评价; 2）确定与新型治疗剂治疗小鼠相关的不良反应。3)提供来自患有自发性肉瘤的狗的高质量正常和肿瘤组织样品;和4）评估新的STATS抑制剂（LY 5）在正常狗和患有自发性骨肉瘤的狗中的不良事件概况和生物活性。